These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 22490358)
1. [The effect of cell killing by ABT-737 synergized with docetaxel in human prostate cancer PC-3 cells]. Hao JW; Mao XP; Ding DG; Du GH; Liu ZH Zhonghua Wai Ke Za Zhi; 2012 Feb; 50(2):161-5. PubMed ID: 22490358 [TBL] [Abstract][Full Text] [Related]
2. Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition. Tamaki H; Harashima N; Hiraki M; Arichi N; Nishimura N; Shiina H; Naora K; Harada M Oncotarget; 2014 Nov; 5(22):11399-412. PubMed ID: 25333266 [TBL] [Abstract][Full Text] [Related]
3. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Chen S; Dai Y; Harada H; Dent P; Grant S Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790 [TBL] [Abstract][Full Text] [Related]
4. [Bcl-2 inhibitor ABT-737 enhances the cisplatin-induced apoptosis in breast cancer T47D cells]. Chen ZJ; Zhang B; Pan SH; Zhao HM; Zhang Y; Feng WH; Li YY; Cao XC Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):891-5. PubMed ID: 22340096 [TBL] [Abstract][Full Text] [Related]
5. Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737. Okumura K; Huang S; Sinicrope FA Clin Cancer Res; 2008 Dec; 14(24):8132-42. PubMed ID: 19088028 [TBL] [Abstract][Full Text] [Related]
6. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis. Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663 [TBL] [Abstract][Full Text] [Related]
7. ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents. Touzeau C; Dousset C; Bodet L; Gomez-Bougie P; Bonnaud S; Moreau A; Moreau P; Pellat-Deceunynck C; Amiot M; Le Gouill S Clin Cancer Res; 2011 Sep; 17(18):5973-81. PubMed ID: 21821698 [TBL] [Abstract][Full Text] [Related]
8. YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context. Jane EP; Premkumar DR; DiDomenico JD; Hu B; Cheng SY; Pollack IF Mol Cancer Ther; 2013 Mar; 12(3):326-38. PubMed ID: 23325792 [TBL] [Abstract][Full Text] [Related]
9. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia. Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332 [TBL] [Abstract][Full Text] [Related]
10. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. Kang MH; Wan Z; Kang YH; Sposto R; Reynolds CP J Natl Cancer Inst; 2008 Apr; 100(8):580-95. PubMed ID: 18398104 [TBL] [Abstract][Full Text] [Related]
11. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Oakes SR; Vaillant F; Lim E; Lee L; Breslin K; Feleppa F; Deb S; Ritchie ME; Takano E; Ward T; Fox SB; Generali D; Smyth GK; Strasser A; Huang DC; Visvader JE; Lindeman GJ Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2766-71. PubMed ID: 21768359 [TBL] [Abstract][Full Text] [Related]
12. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. Miller LA; Goldstein NB; Johannes WU; Walton CH; Fujita M; Norris DA; Shellman YG J Invest Dermatol; 2009 Apr; 129(4):964-71. PubMed ID: 18987671 [TBL] [Abstract][Full Text] [Related]
13. Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation. Rahmani M; Aust MM; Hawkins E; Parker RE; Ross M; Kmieciak M; Reshko LB; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Grant S Haematologica; 2015 Dec; 100(12):1553-63. PubMed ID: 26452980 [TBL] [Abstract][Full Text] [Related]
14. Clitocine induces apoptosis and enhances the lethality of ABT-737 in human colon cancer cells by disrupting the interaction of Mcl-1 and Bak. Sun JG; Xiang J; Zeng XL; Li X; Wu P; Fung KP; Liu FY Cancer Lett; 2014 Dec; 355(2):253-63. PubMed ID: 25304383 [TBL] [Abstract][Full Text] [Related]
15. Combination of ABT-737 and resveratrol enhances DNA damage and apoptosis in human T-cell acute lymphoblastic leukemia MOLT-4 cells. Opydo-Chanek M; Rak A; Cierniak A; Mazur L Toxicol In Vitro; 2017 Aug; 42():38-46. PubMed ID: 28366708 [TBL] [Abstract][Full Text] [Related]
16. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354 [TBL] [Abstract][Full Text] [Related]
17. Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression. Olberding KE; Wang X; Zhu Y; Pan J; Rai SN; Li C Cancer Biol Ther; 2010 Nov; 10(9):918-29. PubMed ID: 20818182 [TBL] [Abstract][Full Text] [Related]
18. Ionizing radiation sensitizes breast cancer cells to Bcl-2 inhibitor, ABT-737, through regulating Mcl-1. Wu H; Schiff DS; Lin Y; Neboori HJ; Goyal S; Feng Z; Haffty BG Radiat Res; 2014 Dec; 182(6):618-25. PubMed ID: 25409124 [TBL] [Abstract][Full Text] [Related]
19. ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway. Li R; Zang Y; Li C; Patel NS; Grandis JR; Johnson DE Mol Pharmacol; 2009 May; 75(5):1231-9. PubMed ID: 19246337 [TBL] [Abstract][Full Text] [Related]
20. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Tahir SK; Yang X; Anderson MG; Morgan-Lappe SE; Sarthy AV; Chen J; Warner RB; Ng SC; Fesik SW; Elmore SW; Rosenberg SH; Tse C Cancer Res; 2007 Feb; 67(3):1176-83. PubMed ID: 17283153 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]